AstraZeneca PLC (AZN)vsViemed Healthcare Inc (VMD)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
VMD
Viemed Healthcare Inc
$9.96
+0.71%
HEALTHCARE · Cap: $380.22M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 21633% more annual revenue ($58.74B vs $270.28M). AZN leads profitability with a 17.4% profit margin vs 5.5%. VMD trades at a lower P/E of 26.7x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
VMD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+57.1%
Fair Value
$19.68
Current Price
$9.96
$9.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Revenue surging 25.5% year-over-year
Earnings expanding 29.8% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
5.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : VMD
The strongest argument for VMD centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 25.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : VMD
The primary concerns for VMD are P/E Ratio, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.16 — expect wider price swings.
VMD is growing revenue faster at 25.5% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 56/100), backed by strong 17.4% margins. VMD offers better value entry with a 57.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?